Company Profile
Nautilus Biotechnology Stock Price, News & Catalysts
- Ticker:
- NAUT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.95 USD (+5.79%)
Close
Last updated: August 21, 2026
341M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, NAUT closed up 5.79% at $0.9545. No new same-company headline was identified in the current news window.
Company overview
Single-Molecule Proteomics Platform
Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteomics platform intended to make comprehensive protein analysis more accessible. The platform is designed to quantify proteins and their proteoforms at scale, supporting research in disease biology, diagnostics, and drug development.
Voyager Instrument Platform
The Nautilus Voyager Platform is the company’s planned commercial instrument system. It is being designed to bring highly multiplexed single-molecule protein analysis into research and drug-development workflows.
Assay-Led Early Access
Before broad instrument availability, Nautilus is engaging customers through its Iterative Mapping Early Access service. The Tau Proteoforms Assay is the first available application, with AKT1 selected as the first oncology-focused proteoform assay.
Instrument and Consumables Model
Nautilus plans to progress from early-access services to a commercial model combining instruments, consumable kits, and targeted proteoform assays. This approach is intended to create recurring demand as the installed instrument base and application menu expand.
Future catalysts
- The AKT1 Proteoforms Assay is expected to enter Iterative Mapping Early Access by the end of 2026.
- Voyager Platform preorders are expected to open in early 2027, with initial instrument shipments planned for mid-2027.
- Consumable kits for the Tau, AKT1, and a second oncology proteoform assay are expected to become generally available in mid-2027, followed by a third oncology assay and additional kits by year-end 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nautilus Biotechnology (NAUT)?
Nautilus Biotechnology (NAUT) most recently closed at 0.95 USD, a +5.79% move versus the previous session.
What is the market cap of Nautilus Biotechnology (NAUT)?
Nautilus Biotechnology currently has a market capitalization of 341M USD on BioPharmSignal.
What does Nautilus Biotechnology do?
Single-Molecule Proteomics Platform Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteomics platform intended to make comprehensive protein analysis more accessible. The platform is designed to quantify proteins and their proteoforms at scale, supporting research in disease biology, diagnostics, and drug...
On which exchange is NAUT stock listed?
Nautilus Biotechnology (NAUT) is associated with NASDAQ, United States, Biopharma.
What is Single-Molecule?
Single-Molecule Proteomics Platform Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteomics platform intended to make comprehensive protein analysis more accessible.
Which conditions is Nautilus Biotechnology targeting with Single-Molecule?
Nautilus Biotechnology is associated with oncology based on its company overview and current catalyst commentary.
How does Nautilus Biotechnology describe recent progress with Single-Molecule?
The AKT1 Proteoforms Assay is expected to enter Iterative Mapping Early Access by the end of 2026. Voyager Platform preorders are expected to open in early 2027, with initial instrument shipments planned for mid-2027. Consumable kits for the Tau, AKT1, and a second oncology proteoform assay are expected to become generally available in mid-2027, followed by...
What is Proteomics?
Single-Molecule Proteomics Platform Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteomics platform intended to make comprehensive protein analysis more accessible.